A股新“医药一哥”盈利在即?百济神州亏损收窄,泽布替尼大卖188亿元,美国市场贡献最大

时代财经
28 Feb

接近百济神州的知情人士向时代财经透露,百济神州未来将通过两条关键路径实现这一目标:一是持续提升销售额,二是加强费用控制。在市值超越恒瑞医药(600276.SH)后,新“医药一哥”百济神州(ONC.US;06160.HK;688235.SH)的业绩表现再次引发市场关注。2月27日晚间,百济神州发布2024年度业绩快报,报告期内,公司营业总收入为272.14亿元,同比增长56.2%;归母净利润为亏损...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10